Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Real-time Estimate Cboe BZX Other stock markets 01:15:11 2026-04-22 pm EDT			5-day change	1st Jan Change
26.86 ^USD	+2.19%		-22.96%	-2.50%

Mar. 31	Agios Shares Rise After Plans for Accelerated Approval Filing of Mitapivat in Sickle Cell Disease	MT
Mar. 31	Agios Pharmaceuticals Announces Plans To Pursue Accelerated Approval For Mitapivat In Sickle Cell Disease	CI

Transcript : Agios Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 08

Published on 01/14/2026 at 12:35 pm EST - Modified on 01/16/2026 at 10:51 pm EST

S&P Capital IQ

Presenter Speech
Tessa Romero (Analysts)

Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Agios Pharmaceuticals, Inc.

Mar. 31	Agios Shares Rise After Plans for Accelerated Approval Filing of Mitapivat in Sickle Cell Disease	MT
Mar. 31	Agios Pharmaceuticals Announces Plans To Pursue Accelerated Approval For Mitapivat In Sickle Cell Disease	CI
Mar. 31	Agios Pharmaceuticals Plans Accelerated Approval Filing for Mitapivat in Sickle Cell Disease	MT
Mar. 02	Agios' Pyrukynd® (mitapivat) approved for adults with thalassemia in the United Arab Emirates	RE
Mar. 02	Agios Pharmaceuticals Says Pyrukynd Thalassemia Treatment Approved by UAE Drug Regulator	MT
Mar. 02	Agios Pharmaceuticals, Inc.'S Pyrukynd®? Approved for Adults with Thalassemia in the United Arab Emirates	CI
Feb. 12	Agios Pharmaceuticals, Inc., Q4 2025 Earnings Call, Feb 12, 2026
Feb. 12	Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 12	Agios Pharmaceuticals Q4 Revenue Rises	MT
Feb. 12	Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q4 Revenue $20.0M, vs. FactSet Est of $12.1M	MT
Jan. 14	Agios Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 08:15 AM
Jan. 06	BofA Adjusts Price Target on Agios Pharmaceuticals to $35 From $34, Maintains Buy Rating	MT
Jan. 05	Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026	CI
Dec. 24	Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal	MT
Dec. 24	Agios Shares Rise After FDA Approves Aqvesme to Treat Anemia in Thalassemia Patients	MT